A third SARS-CoV-2 mRNA vaccine dose in people receiving hemodialysis overcomes B cell defects but elicits a skewed CD4<sup>+</sup> T cell profile.
Details
State: Public
Version: Final published version
License: CC BY-NC-ND 4.0
Serval ID
serval:BIB_B9943D70F95B
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
A third SARS-CoV-2 mRNA vaccine dose in people receiving hemodialysis overcomes B cell defects but elicits a skewed CD4<sup>+</sup> T cell profile.
Journal
Cell reports. Medicine
ISSN
2666-3791 (Electronic)
ISSN-L
2666-3791
Publication state
Published
Issued date
21/03/2023
Peer-reviewed
Oui
Volume
4
Number
3
Pages
100955
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Abstract
Cellular immune defects associated with suboptimal responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccination in people receiving hemodialysis (HD) are poorly understood. We longitudinally analyze antibody, B cell, CD4 <sup>+</sup> , and CD8 <sup>+</sup> T cell vaccine responses in 27 HD patients and 26 low-risk control individuals (CIs). The first two doses elicit weaker B cell and CD8 <sup>+</sup> T cell responses in HD than in CI, while CD4 <sup>+</sup> T cell responses are quantitatively similar. In HD, a third dose robustly boosts B cell responses, leads to convergent CD8 <sup>+</sup> T cell responses, and enhances comparatively more T helper (T <sub>H</sub> ) immunity. Unsupervised clustering of single-cell features reveals phenotypic and functional shifts over time and between cohorts. The third dose attenuates some features of T <sub>H</sub> cells in HD (tumor necrosis factor alpha [TNFα]/interleukin [IL]-2 skewing), while others (CCR6, CXCR6, programmed cell death protein 1 [PD-1], and HLA-DR overexpression) persist. Therefore, a third vaccine dose is critical to achieving robust multifaceted immunity in hemodialysis patients, although some distinct T <sub>H</sub> characteristics endure.
Keywords
Humans, COVID-19 Vaccines, SARS-CoV-2/genetics, COVID-19/prevention & control, CD4-Positive T-Lymphocytes, B cell immunity, COVID-19, Hemodialysis, Immune cell phenotyping, SARS-CoV-2, T cell immunity, Vaccine response, mRNA vaccine
Pubmed
Web of science
Open Access
Yes
Create date
13/03/2023 12:49
Last modification date
25/01/2024 8:43